Author Archive: Jason Corum

Jason Corum

Jason is the director of web and new media with the Biotechnology Industry Organization (BIO). Prior to joining BIO in March 2011, he was the online communications manager for World Food Program USA and an online communications specialist with the Brookings Institution.

Jason is originally from Evergreen Park, Ill. and still thinks that Chicago is the best food city in the nation.  He spends his free time volunteering with the DC Books to Prisons Project, watching movies and reading comics.

Latest Posts

How to Drive International Innovation: Scientific American Worldview

Worldview Super Session

Which countries are winning the innovation game? Will the U.S. maintain its leadership position in the future? Have emerging markets lived up to the hype? Which new partnerships are transforming industries? For the fifth year, Scientific American (SA) released their Worldview: A Global Biotechnology Perspective report at the 2013 BIO International Convention in Chicago. Included in this year’s report is the longest list of country rankings that SA has ever compiled and the numbers reveal Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Your Social Media Guide to #BIO2013

Twitter Bird

The BIO International Convention is the largest global event for the biotechnology industry; it attracts the biggest names in biotech and offers key networking and partnering opportunities. The event is also a great opportunity to connect with the online biotech community and we’re ramping up our social media efforts for the 2013 BIO International Convention, beginning on Monday, April 22 in Chicago. If you’d like to join the online conversation, here are some tips, tricks, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Small Biotech Companies and China: 5 Keys to Success

BIO CEO

Big pharmaceutical countries aren’t the only ones investing in China. Emerging and mid-sized biotech companies are also exploring ways to enter China’s lucrative market and maximize their investment in the country. With limited resources, how can smaller companies operate efficiently and give Chinese patients access to their innovative products? A panel of experts explored these questions at the 2013 BIO CEO & Investor Conference. Jimmy Zhang from Merck moderated a panel including: Friedhelm Blobel, PhD, President, CEO, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

How to Survive the Patent Cliff: Eli Lilly’s CEO at the BIO CEO & Investor Conference

Fireside Chat

Like a number of companies, Eli Lilly is confronting a wave of patent expirations called the patent cliff. The company lost U.S. patent protection on the anti-psychotic Zyprexa in the fall of 2011 and they’re facing the losses of the antidepressant Cymbalta in December of 2013 and the osteoporosis drug Evista in 2014. The loss of protection endangers the company’s ability to profit from the drugs and they could face a $25 billion loss in Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Celgene CEO on New Multiple Myeloma Drug Approvals

BIO CEO

Following on the heels of two big announcements in February, Celgene CEO Robert Hugin (one of FierceBiotech’s most influential people in biopharma) participated in a fireside chat with Joel Sendek, managing director and biotechnology analyst at Stifel Nicolaus & Company, at the 15th Annual BIO CEO & Investor Conference in New York. First, on Friday, February 8, the Food and Drug Administration (FDA) approved Celgene’s drug Pomalyst for patients with multiple myeloma whose disease has Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,